WC
IOVA icon

Wexford Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Wexford Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-104,391
Closed -$1.99M – 185
2021
Q4 		$1.99M Buy
+104,391
New +$2.3M 0.08% 83
2021
Q2 		$2.72M Buy
+104,391
New +$2.71M 0.41% 56

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Wexford Capital's IOVA Position: Q1 2022 in Review

Wexford Capital sold out of Iovance Biotherapeutics (IOVA) in Q1 2022, closing a stake of 104,391 shares — an estimated $1.99M sold.

Wexford Capital first reported a position in IOVA in Q2 2021 and held it in 2 quarters. The position peaked at $2.72M in Q2 2021. 250 funds tracked by Wall St. Rank hold IOVA as of Q1 2022.

  • Wexford Capital reported no remaining Iovance Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Wexford Capital sold 104,391 Iovance Biotherapeutics shares in Q1 2022, an estimated $1.99M.
  • Wexford Capital first reported a position in Iovance Biotherapeutics in Q2 2021 and held it in 2 quarters.
  • Wexford Capital's Iovance Biotherapeutics position peaked at $2.72M in Q2 2021.
  • 250 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2022.

Based on Wexford Capital's 13F filing for Q1 2022, filed 13 May 2022.